You are here » About Galderma » Company History

Company History

Dermatology company Galderma’s detailed timeline:

 

2013

Acquisition of Swiss company Spirig AG, maker of Daylong & Excipial.
FDA approval of Mirvaso for the treatment of erythema associated with rosacea.

2012

Galderma defines its new 3-business-strategy and a new ambition statement.
Opening of a new affiliate in China.
Cetaphil Dermacontrol is launched in 6 countries.

2011

Acquisition of Q-Med, a Swedish company specialized in aesthetic & corrective solutions.
Emervel (dermal filler range) launch in Europe and Latin America.
Plant extensions in France and Canada.

2010

Galderma hits the 1 billion mark in sales.
Launch of Cetaphil Restoraderm. Launch of Restylane Skincare series with NASHA™
Differin Lotion 0.1% (acne) launch in the United States.

2009

Launch of Vectical (psoriasis), Azzalure (glabellar lines) and Restylane Injector, a new type of injection device which simplifies the rejuvenation treatment and wins the prestigious Red Dot Design Award.
Galderma purchases global rights, assets, and liabilities related to Metvix and Aktilite.
Restylane obtains registration approval in China and becomes the first injectable non-animal hyaluronic acid product on the Chinese market.

2008

Launch of Epiduo (acne).
Acquisition of CollaGenex Pharmaceuticals
and its product Oracea (rosacea).
Launch of Differin 0.1% in Japan.

2007

Licensing agreements for abotulinum toxin type A andPliaglis (topical anesthetic).
Launch of Differin 0.3%.

2006

Clobex Spray launch in the US.
Opening of the new R&D center in Sophia Antipolis, France.

2005

Metrogel 1% (rosacea) launch in the United-States.
For the first time, Galderma ranks Number One in D class in its markets
(source: IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries).

2004

Inauguration of the new research and preclinical development building in Sophia Antipolis, France.
Opening of a new production site in Hortolandia, Brazil.
Clobex Shampoo launch in the United-States and acquisition of Tri-Luma.

2003

Launch of Metvix in Germany and the UK and Clobex Lotion (psoriasis) in the US.
Restylane® is approved in the US.

2002

Licensing agreements for Tri-Luma (pigmentary disorders) and Pekiron (Loceryl Cream) in Japan.
First FDA approvals for pharmaceutical production in Montreal.

2001

Licensing agreement for Metvix (skin cancer).
Launch of Clindagel (acne).

2000

The Montreal production unit comes on stream.
Launch of Silkis (psoriasis) and acquisition of Capex Shampoo (seborrheic dermatitis).

1999

Acquisition of Loceryl (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed.

1998

Inauguration of a new R&D facility in Princeton, New Jersey, USA.
Acquisition in Brazil of Darrow’s dermatology portfolio.

1997

Acquisition of Basotherm, a subsidiary of Boehringer.

1996

Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant.
Restylane is approved for sales in Europe, for filling out of wrinkles and lip augmentation.

1995

Launch of anti-acne treatment Differin, Galderma’s first home-grown dermatology product.
The NASHA patent is filed.

1994

Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.

1993

Acquisition of MetroGel / Rozex to include rosacea treatments in the product portfolio.

1989

Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom.

1988

Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology.

1987

Q-Med is founded by Bengt Ågerup with a view to commercializing the research that he had carried out around hyaluronic acid.

1986

Galderma’s first affiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products.

1981

Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born.

1979

L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology.

1977

Nestlé acquires Alcon to strengthen its presence in the North American market.

1972

Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas.

1961

Creation of the Owen dermatology company in Dallas, Texas, USA


Discover more about Galderma, a dermatology company providing dermatology solutions and aesthetic and corrective products internationally.

Follow us Follow us on twitter Follow us on Linkedin

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world

Read

Video

We are committed

See all videos